CM
CRNX icon

Caption Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Caption Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-150,000
Closed -$5.03M – 1531
2025
Q1 		$5.03M Buy
+150,000
New +$5.6M 0.05% 391
2024
Q2 		– Sell
-43,900
Closed -$2.05M – 1221
2024
Q1 		$2.05M Sell
43,900
-78,900
-64% -$3.09M 0.03% 523
2023
Q4 		$4.37M Buy
122,800
+106,400
+649% +$3.26M 0.06% 380
2023
Q3 		$488K Buy
+16,400
New +$338K 0.01% 940

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Caption Management's CRNX Position: Q2 2025 in Review

Caption Management sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2025, closing a stake of 86,713 shares — an estimated $2.68M sold.

Caption Management first reported a position in CRNX in Q4 2023 and held it in 2 quarters. The position peaked at $2.91M in Q1 2025. 222 funds tracked by Wall St. Rank hold CRNX as of Q2 2025.

  • Caption Management reported no remaining Crinetics Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Caption Management sold 86,713 Crinetics Pharmaceuticals shares in Q2 2025, an estimated $2.68M.
  • Caption Management first reported a position in Crinetics Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Caption Management's Crinetics Pharmaceuticals position peaked at $2.91M in Q1 2025.
  • 222 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2025.

Based on Caption Management's 13F filing for Q2 2025, filed 14 Aug 2025.